Cell Source Inc. (CLCS) 1.3900 $CLCS
Cell Source Appoints Dr. Robert Negrin to Its Scientific Advisory Board
Marketwired - Mon Jul 06, 7:31AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Robert S. Negrin, Director of the Bone and Marrow Transplantation Division and Professor of Medicine at Stanford University, has joined its Scientific Advisory Board.
Cell Source Appoints Dr. Steven Burakoff to Its Scientific Advisory Board
Marketwired - Mon Jun 29, 7:30AM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Steven Burakoff, Director of the Tisch Cancer Institute at Mount Sinai Medical Center and Professor of Cancer Medicine and Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, has joined its Scientific Advisory Board.
World Class Immunologist Dr. Herman Waldmann Joins Cell Source's Scientific Advisory Board
Marketwired - Wed Jun 17, 7:31AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Herman Waldman, who served as Department Head and Professor Emeritus of Pathology at the Oxford Medical School and Clinical Director of Oxford's Therapeutic Antibody Centre, has joined the Cell Source Scientific Advisory Board.
Cell Source names Dr Terry Strom as SAB chair
M2 - Fri Jun 05, 4:52AM CDT
Biotechnology company Cell Source (OTCBB:CLCS) revealed on Thursday the addition of Dr Terry Strom as chairman of its Scientific Advisory Board (SAB).
Cell Source Appoints Dr. Terry Strom as Chairman of Its Scientific Advisory Board
Marketwired - Thu Jun 04, 10:22AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Terry Strom, Professor of Medicine and Surgery at Harvard Medical School and Director of The Transplant Institute at Beth Israel Deaconess Medical Center, has been retained to serve as Chairman of its Scientific Advisory Board.
Cell Source to Present at the 2015 Marcum MicroCap Conference
Marketwired - Fri May 22, 1:01PM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that it will present at the 2015 Marcum MicroCap Conference on Thursday, May 28th, 2015 in New York City at the Grand Hyatt Hotel.
Cell Source, Inc. Announces the Launch of Its New Investor Relations Website
Marketwire Canada - Fri May 22, 12:52PM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, unveiled its new Investor Relations website. The site, (ir.cell-source.com), incorporates numerous features to make browsing for investment information a much faster and informative experience for the Company's current and potential investors.
Cell Source Retains Strategic Patent Advisor Dr. Michael B. Farber
ACCESSWIRE - Wed May 20, 7:30AM CDT
NEW YORK, NY / ACCESSWIRE / May 20, 2015 / Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Michael B. Farber, a Partner with Ditthavong & Steiner P.C. has been retained as Strategic Patent Advisor to the Company. The company's patented "Veto Cell" technology, is licensed exclusively from Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science in Israel.
Cell Source to Present at the Roth Capital Conference in Dana Point, CA on March 10, 2015
ACCESSWIRE - Mon Mar 09, 10:22PM CDT
TEL AVIV, ISRAEL / ACCESSWIRE / March 9, 2015 / Cell Source, Inc. (OTCQB:CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at the Roth Conference on Tuesday, March 10, 2015 at 5:30pm in Dana Point, California.
Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials
PR Newswire - Thu Nov 13, 3:00AM CST
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source" an immunotherapy and regenerative medicine company, announced today its Megadose Drug Combination has been cleared for human clinical trials in Italy. Cell Source's proprietary Megadose Drug Combination is expected to increase bone marrow transplantation (BMT) success and survival. By combining an established cell therapy with U.S. Food and Drug Administration (FDA) approved drugs, Megadose Drug Combination, based on preclinical results to date, may have the potential to enable an improvement in the effectiveness and safety of use of mismatched BMT. BMT is most often used for the treatment of blood cancers and is currently reserved mostly for patients with life threatening diseases, due to complications including transplant rejection. Should BMT become safer, the procedure's use may well be expanded beyond cancer to other indications including genetic and autoimmune disease.
Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 57.95 (+0.57), SHPG: 250.34 (+7.35)
Cell Source to Present at the FireRock Conference and the Life Sciences Summit in New York City on October 28th and 29th, 2014
PR Newswire - Wed Oct 08, 6:00AM CDT
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source" an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at two upcoming conferences in New York City during the month of October.
Cell Source to Present at Rodman & Renshaw Global Investment Conference in New York City on September 10, 2014
PR Newswire - Wed Sep 03, 12:52PM CDT
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source" an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at the Rodman & Renshaw 16th Annual Global Investment Conference which will take place at the New York Palace Hotel in New York City on September 8th through 10th, 2014. Mr. Shimrat is scheduled to present at 9.35 am on Wednesday, September 10th.
Cell Source Appoints Dr. Robert Negrin to Its Scientific Advisory Board
Marketwired - Mon Jul 06, 7:31AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Robert S. Negrin, Director of the Bone and Marrow Transplantation Division and Professor of Medicine at Stanford University, has joined its Scientific Advisory Board.
Cell Source Appoints Dr. Steven Burakoff to Its Scientific Advisory Board
Marketwired - Mon Jun 29, 7:30AM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Steven Burakoff, Director of the Tisch Cancer Institute at Mount Sinai Medical Center and Professor of Cancer Medicine and Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, has joined its Scientific Advisory Board.
World Class Immunologist Dr. Herman Waldmann Joins Cell Source's Scientific Advisory Board
Marketwired - Wed Jun 17, 7:31AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Herman Waldman, who served as Department Head and Professor Emeritus of Pathology at the Oxford Medical School and Clinical Director of Oxford's Therapeutic Antibody Centre, has joined the Cell Source Scientific Advisory Board.
Cell Source names Dr Terry Strom as SAB chair
M2 - Fri Jun 05, 4:52AM CDT
Biotechnology company Cell Source (OTCBB:CLCS) revealed on Thursday the addition of Dr Terry Strom as chairman of its Scientific Advisory Board (SAB).
Cell Source Appoints Dr. Terry Strom as Chairman of Its Scientific Advisory Board
Marketwired - Thu Jun 04, 10:22AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Terry Strom, Professor of Medicine and Surgery at Harvard Medical School and Director of The Transplant Institute at Beth Israel Deaconess Medical Center, has been retained to serve as Chairman of its Scientific Advisory Board.
Cell Source to Present at the 2015 Marcum MicroCap Conference
Marketwired - Fri May 22, 1:01PM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that it will present at the 2015 Marcum MicroCap Conference on Thursday, May 28th, 2015 in New York City at the Grand Hyatt Hotel.
Cell Source, Inc. Announces the Launch of Its New Investor Relations Website
Marketwire Canada - Fri May 22, 12:52PM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, unveiled its new Investor Relations website. The site, (ir.cell-source.com), incorporates numerous features to make browsing for investment information a much faster and informative experience for the Company's current and potential investors.
Cell Source Retains Strategic Patent Advisor Dr. Michael B. Farber
ACCESSWIRE - Wed May 20, 7:30AM CDT
NEW YORK, NY / ACCESSWIRE / May 20, 2015 / Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Michael B. Farber, a Partner with Ditthavong & Steiner P.C. has been retained as Strategic Patent Advisor to the Company. The company's patented "Veto Cell" technology, is licensed exclusively from Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science in Israel.
Cell Source to Present at the Roth Capital Conference in Dana Point, CA on March 10, 2015
ACCESSWIRE - Mon Mar 09, 10:22PM CDT
TEL AVIV, ISRAEL / ACCESSWIRE / March 9, 2015 / Cell Source, Inc. (OTCQB:CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at the Roth Conference on Tuesday, March 10, 2015 at 5:30pm in Dana Point, California. Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials
PR Newswire - Thu Nov 13, 3:00AM CST
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its Megadose Drug Combination has been cleared for human clinical trials in Italy. Cell Source's proprietary Megadose Drug Combination is expected to increase bone marrow transplantation (BMT) success and survival. By combining an established cell therapy with U.S. Food and Drug Administration (FDA) approved drugs, Megadose Drug Combination, based on preclinical results to date, may have the potential to enable an improvement in the effectiveness and safety of use of mismatched BMT. BMT is most often used for the treatment of blood cancers and is currently reserved mostly for patients with life threatening diseases, due to complications including transplant rejection. Should BMT become safer, the procedure's use may well be expanded beyond cancer to other indications including genetic and autoimmune disease. Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 57.95 (+0.57), SHPG: 250.34 (+7.35)
Cell Source to Present at the FireRock Conference and the Life Sciences Summit in New York City on October 28th and 29th, 2014
PR Newswire - Wed Oct 08, 6:00AM CDT
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at two upcoming conferences in New York City during the month of October. Cell Source to Present at Rodman & Renshaw Global Investment Conference in New York City on September 10, 2014
PR Newswire - Wed Sep 03, 12:52PM CDT
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at the Rodman & Renshaw 16th Annual Global Investment Conference which will take place at the New York Palace Hotel in New York City on September 8th through 10th, 2014. Mr. Shimrat is scheduled to present at 9.35 am on Wednesday, September 10th. 
